EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Parathyroid carcinoma: from molecular pathogenesis to multidisciplinary management

Jia-xi Song, Yu-ying Yang, Jin-xin Zhou, Jing Xie, Hao-ji Gao, Min-ting Zhu, Bei Tao, Xi Chen, Li-hao Sun, Jian-min Liu

The Journal of Clinical Endocrinology & Metabolism · 2026-10-16 · 111 (11) · 3012-3031

DOI: 10.1210/clinem/dgag266 ↗
AbstractBibliografische Angaben

Abstract

Abstract Parathyroid carcinoma (PC) is a rare malignancy accounting for <1% of primary hyperparathyroidism cases. This review summarizes current knowledge on its molecular pathogenesis, diagnosis, imaging, management and prognosis. PC is driven primarily by CDC73 mutations with loss of parafibromin expression, with emerging roles for PI3K/AKT/mTOR and Wnt pathway alterations. Its diagnosis remains challenging. Clinical suspicion should arise with marked hypercalcemia, elevated PTH, palpable neck mass or recurrent laryngeal nerve palsy. Imaging modalities including cervical ultrasound, 99mTc-sestamibi, 4D-CT, and [18F]fluorocholine PET/CT aid localization and metastasis detection. En bloc resection with ipsilateral thyroid lobectomy is the standard approach. Traditional medical therapies are helpful in reducing serum calcium level. Radiotherapy and chemotherapy have limited efficacy. Targeted therapies and immunotherapy show promise in advanced disease, however, the such evidence is weak. Recurrence rates of 23% to 65% mandate lifelong follow-up. Prognostic factors include surgical approach, postoperative remission, Ki-67 index, as well as parafibromin status and mTOR activation. Multidisciplinary management in specialized centers is critical for optimizing outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →